Ide-cel vs Standard Regimens for Patients With Relapsed and Refractory Multiple Myeloma
Posted: 04/19/2023 | By: Sarah Campen, PharmD

A phase III trial—results of which were published by Rodriguez-Otero in The New England Journal of Medicine—compared the efficacy of idecabtagene vicleucel (ide-cel), a chimeric antigen receptor (CAR) T-cell therapy, to five other standard regimens in patients with relapsed and refractory multiple myeloma.

Question 1 of 5

What is the target antigen for idecabtagene vicleucel (ide-cel)?

Choose 1